文献速递血液淋巴病理细胞病理与分子病理

淋巴结细胞病理学:淋巴增殖性肿瘤必备辅助检查

Lymph node cytopathology: Essential ancillary studies as applied to lymphoproliferative neoplasms.
PubMed 文献 · Cancer Cytopathol · 2018-01-01

本文综述了细针穿刺(FNA)活检在淋巴增殖性肿瘤诊断与分类中辅助检查的应用。免疫表型(流式细胞术和/或免疫组化)是新诊断及复发/难治患者启动治疗前的标准。FNA材料适于满足此需求,但部分淋巴瘤因需明确淋巴结结构、组织学分级或分子检测受限而难以 definitive 分型。文章还讨论了作者实验室处理淋巴结穿刺液的诊断流程与算法,并列出有限的与扩展的抗体组合及分子检测。

要点

  • FNA联合流式细胞术和/或免疫组化是淋巴瘤诊断分型的标准辅助检查。
  • 部分淋巴瘤(如霍奇金淋巴瘤、滤泡性淋巴瘤)因需结构或分级信息而难以仅凭FNA分型。
  • 分子检测在淋巴结穿刺中的应用仍在发展中,多限于专业医疗中心。

核心结论

  • 辅助检查对于FNA所获淋巴增殖性肿瘤的正确识别与分类至关重要。

研究设计与样本

  • 本文为综述,回顾作者实验室处理淋巴结穿刺液的诊断方法与算法。

主要发现

  • 免疫表型(流式细胞术和/或免疫组化)是新诊断及复发/难治淋巴瘤患者启动治疗前的标准。
  • FNA材料适于免疫表型分析,但部分淋巴瘤因需明确淋巴结结构、组织学分级或分子检测受限而难以 definitive 分型。
  • 分子检测在淋巴结穿刺中的应用仍在发展,但多限于专业医疗中心。

关键数值与推荐

  • 文中列出了作者认为有用的有限与扩展抗体组合及分子检测,用于识别和尽可能分型淋巴瘤。

临床怎么用

  • 对FNA淋巴结标本应常规进行流式细胞术和/或免疫组化以进行免疫表型分析。
  • 在部分淋巴瘤中,需结合结构、分级或分子信息,FNA可能无法单独分型。

局限性

  • FNA无法评估淋巴结结构,限制霍奇金淋巴瘤等诊断。
  • 滤泡性淋巴瘤分级需计数每显微镜视野细胞数,FNA难以实现。
  • 分子检测常因细胞量限制而无法进行,且多限于专业中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ancillary testing is absolutely integral to the correct recognition and classification of lymphoid neoplasms as procured with the fine-needle aspiration (FNA) biopsy technique. In patients with a newly diagnosed lymphoid neoplasm, immunophenotyping with flow cytometry, immunohistochemistry, or both is a standard that is currently expected by oncologists before any form of therapy is initiated. This is often the case also for patients with recurrent/relapsed disease. The cellular material obtained with FNA is perfectly suited to meet this demand. That said, the exceptional complexity of modern-day lymphoma classification often precludes definitive subclassification in a subset of lymphomas for a variety of reasons with the FNA biopsy technique, even with the application of ancillary tests. These include a requirement for definitive knowledge of the nodal architecture (eg, Hodgkin lymphoma), of the histologic grade via the counting of cells per microscopic field (follicular lymphoma), and of molecular findings (often unobtainable because of limitations of cellularity). The application of molecular tests to lymph node aspirates continues to evolve but is still largely confined to specialized medical centers. The intent of this article is to briefly review the diagnostic approach and algorithm for handling lymph node aspirates at the authors' own laboratory. This article highlights what the authors and others consider to be essential ancillary tests and discusses their respective advantages and shortcomings. It lists limited and extended antibody panels and molecular tests that the authors have found helpful not only for correctly recognizing lymphoma with FNA cytopathology but also for subtyping lymphomas whenever possible.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Jin M, Wakely PE. Lymph node cytopathology: Essential ancillary studies as applied to lymphoproliferative neoplasms. Cancer Cytopathol. 2018. PMID: 30156771. doi:10.1002/cncy.22013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。